Latest Commercial Partnerships News

Patrys Limited has appointed Dr Samantha South as its new CEO, aiming to leverage her biotech expertise to fast-track clinical development and commercialisation of its therapeutic antibody pipeline.

Connexion Mobility Ltd reported a 7% rise in revenues and a 5% increase in profit after tax for the half-year ended December 2025, while expanding its SaaS footprint and acquiring a strategic stake in Covertrue Group.

Epsilon Healthcare’s subsidiary, Epsilon Pharma, has signed a three-year manufacturing agreement with New Zealand’s Puro to supply medicinal cannabis products to the UK and Europe, marking a significant step in its international expansion.

Adisyn Ltd has appointed Arye Kohavi, CEO of 2D Generation, as its new Managing Director to spearhead its semiconductor technology strategy following a strategic review and recent acquisition.

Rhythm Biosciences has secured a multi-year commercial manufacturing agreement with US-based Quansys Biosciences to produce ColoSTAT® reagent kits, paving the way for broader market rollout of its colorectal cancer diagnostic test.

Invion Limited has secured a $2 million non-dilutive grant from the South Korean government to advance preclinical studies for oesophageal cancer, expanded its global Photosoft technology license, and raised $1.3 million via convertible notes to strengthen its financial position.

Vulcan Energy Resources has locked in a €2.2 billion financing package to propel its Phase One Lionheart lithium and renewable energy project in Germany, marking a major step towards Europe’s first fully domestic sustainable lithium supply chain.

Sparc Technologies has marked a significant milestone with sustained hydrogen production at its pioneering pilot plant and secured key patents, while also achieving its first commercial sale of graphene additives.

TrivarX Limited has expanded its diagnostic portfolio by acquiring the Stabl-Im brain cancer imaging technology and reported strong clinical trial results validating its single-lead ECG algorithm for depression screening in US veterans.

Bio-Gene Technology Limited reports strong progress in advancing its Flavocide® and Qcide® insecticidal platforms, backed by US Department of Defense funding and key organic certification in the US.

Decidr AI Industries has solidified its position in the agentic AI market by completing strategic acquisitions and launching its DecidrOS platform, achieving a 60% revenue increase in the December quarter.

Avecho Biotechnology is on the cusp of completing patient dosing in its pivotal Phase III CBD insomnia trial, backed by a recent $2.5 million capital raise and patent allowances in the US and Europe.